Loading...
•
Mar 31
Celcuity Q1 2025 Earnings Report
Celcuity reported a larger net loss in Q1 2025 due to increased R&D and administrative expenses as it advanced multiple clinical trials.
Key Takeaways
Celcuity posted a net loss of $37.0 million for Q1 2025, primarily driven by a significant increase in research and development expenses related to its Phase 3 trials. Despite no reported revenue, the company maintained a strong cash position of over $205 million, sufficient to fund clinical programs through 2026. The company expects multiple data readouts from its ongoing studies later this year.
Net loss increased to $37.0 million compared to $21.6 million in Q1 2024.
Research and development expenses rose to $32.2 million, up from $20.6 million.
Cash, cash equivalents, and investments totaled $205.7 million at quarter-end.
Non-GAAP net loss was $34.7 million, excluding stock-based compensation and other non-cash items.
Celcuity
Celcuity
Forward Guidance
Celcuity anticipates key clinical milestones in 2025 and is adequately funded to support its development programs through 2026.
Positive Outlook
- Topline data from VIKTORIA-1 WT cohort expected in Q3 2025.
- PIK3CA mutant cohort data expected in Q4 2025.
- VIKTORIA-2 trial set to begin dosing in Q2 2025.
- Strong cash position of $205.7 million.
- Collaboration with Dana Farber and MGH initiated for endometrial cancer study.
Challenges Ahead
- Significantly increased operating expenses.
- Lack of revenue generation in the quarter.
- Net loss widened compared to prior year.
- High dependency on trial outcomes for future progress.
- Ongoing need for capital to sustain long-term pipeline.